Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease

Author： Breccia Massimo   Lo-Coco Francesco  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.7, 2012-05, pp. : 1031-1043

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tretinoin plus arsenic trioxide: front-line therapy for APL

By  

Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Arsenic trioxide: Secondary cancer in patients with acute promyelocytic leukaemia?: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1138, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Strategies for the Treatment of Acute Promyelocytic Leukemia

By Frankfurt Olga   Tallman Martin S.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 37-50

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Preparation of Arsenic Trioxide-Loaded Microemulsion and Its Enhanced Cytotoxicity on MCF-7 Breast Carcinoma Cell Line

By Yeşim Karasulu H.   Karabulut Bülent   Kantarci Gülten   Özgüney Işik   Sezgin Canfeza   Sanli Ulus   Göker Erdem  

Drug Delivery, Vol. 11, Iss. 6, 2004-11 ,pp. : 345-350

Informa Healthcare

Access to resources Recommend Favorite

Alemtuzumab superior to chlorambucil for front-line CLL therapy

By  

Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite